Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Transcription factors are involved in a large number of human diseases such as cancers for
which they account for about 20% of all oncogenes identified so far. For long time, with the …

Gene activation by mammalian transcription factors (TFs) requires multivalent interactions of
their low-complexity domains (LCDs), but how such interactions regulate transcription …

Marine natural products have proven, over the last half‐century, to be effective biological
modulators. These molecules have revealed new targets for cancer therapy as well as …

While promising, immunotherapy has yet to be fully unlocked for the preponderance of
cancers where conventional chemoradiation reigns. This remains particularly evident in …

The oncogenic transcription inhibitor lurbinectedin (ZEPZELCA™) is being developed by
PharmaMar as a treatment for various cancers. The drug has been granted orphan drug …

Purpose: The importance of cellular context to the synergy of DNA damage response (DDR)-
targeted agents is important for tumors with mutations in DDR pathways, but less well …

Purpose: Lurbinectedin suppresses the oncogenic transcription factor EWS-FLI1 through
relocalization to the nucleolus, and delays tumor growth in mice bearing Ewing sarcoma …

Biomolecular condensates are compartmentalized communities of biomolecules, which
unlike traditional organelles, are not enclosed by membranes. Condensates play roles in …

While sarcomas account for approximately 1% of malignant tumors of adults, they are
particularly more common in children and adolescents affected by cancer. In contrast to …